ºÒ¸éÁõ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Çâ, ¿¹Ãø : Ä¡·á À¯Çü, ¾à¹° Á¾·ùº°, À¯Åë ä³Î, Áö¿ªº°(2025-2033³â)
Insomnia Market Size, Share, Trends and Forecast by Therapy Type, Drug Class, Distribution Channel, and Region, 2025-2033
»óǰÄÚµå
:
1702264
¸®¼Ä¡»ç
:
IMARC Group
¹ßÇàÀÏ
:
2025³â 04¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 150 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
ºÒ¸éÁõ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 53¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â±îÁö 67¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2025³âºÎÅÍ 2033³â±îÁö 2.55%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÇöÀç ºÏ¹Ì°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, 2024³â¿¡´Â 36.4% ÀÌ»óÀÇ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. Çö´ëÀÎÀÇ ¶óÀÌÇÁ½ºÅ¸Àϰú ½ºÆ®·¹½º·Î ÀÎÇÑ °Ç° °ü¸®¿¡ ´ëÇÑ °ü½É Áõ°¡, Áø´Ü ±â¼úÀÇ ¹ßÀüÀ¸·Î ÀÎÇÑ Á¤È®µµ Çâ»ó, »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇÑ À¯·ÂÇÑ ¿¬±¸, ÀÇ·áºñ Áõ°¡, µðÁöÅÐ °Ç° ¼Ö·ç¼ÇÀÇ ÅëÇÕ, Àü·«Àû ¾÷°è Á¦ÈÞ, ºñ¾à¹° ¿ä¹ý¿¡ ´ëÇÑ ¼ÒºñÀÚ ¼±È£µµ Áõ°¡ µîÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ ÷´Ü ÇコÄɾî, ¼ö¸é Àå¾ÖÀÇ ³ôÀº À¯º´·ü, Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÇ Ã¤ÅÃÀÌ ºÒ¸éÁõ ½ÃÀå Á¡À¯À²À» ´õ¿í ³ôÀ̰í ÀÖ½À´Ï´Ù.
ºÒ¸éÁõÀº ¿¡³ÊÁö ¼öÁØÀ» ³·Ãß°í °³ÀÎÀÇ ±âºÐ, °Ç°, ¾÷¹« ¼öÇà ¹× Àü¹ÝÀûÀÎ »îÀÇ Áú¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¼ö¸é Àå¾ÖÀÔ´Ï´Ù. ÀϹÝÀûÀÎ ¿øÀÎÀ¸·Î´Â ½ºÆ®·¹½º, Àå±â ¿©Çà, ¹Ù»Û ¾÷¹« ÀÏÁ¤, ¼ö¸é ½À°ü Àå¾Ö, ÆøÀ½, Æø½Ä, ´ÏÄÚÆ¾, Ä«ÆäÀÎ, ¾ËÄÚ¿Ã °ú´Ù ¼·Ãë µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿Ü»ó ÈÄ ½ºÆ®·¹½º¿Í °°Àº Á¤½ÅÁúȯ, õ½ÄÀ̳ª Ç÷¾ÐÀ» À§ÇÑ Ç׿ì¿ïÁ¦, ÁøÅëÁ¦, ¾Ë·¹¸£±â, °¨±â¾àÀ» À§ÇÑ ÀϹÝÀǾàǰ(OTC) µîÀÇ ¾à¹°ÀÇ »ç¿ë°úµµ °ü·ÃÀÌ ÀÖÀ» ¼ö ÀÖ½À´Ï´Ù. ÀÎÁöÇൿġ·á(CBT), OTC ¼ö¸é º¸Á¶Á¦, ¿¡½ºÁ¶ÇÇÅ©·ÐÀ̳ª ¶ó¸áÅ׿°ú °°Àº ó¹æ¾à µî ´Ù¾çÇÑ Ä¡·á ¿É¼ÇÀÌ ÇöÀç Àü ¼¼°èÀûÀ¸·Î Á¦°øµÇ°í ÀÖ½À´Ï´Ù.
ºÒ¸éÁõ ½ÃÀå µ¿Çâ:
Äڷγª ¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ´ëÀ¯ÇàÀº »çȸÀû °í¸³, ¼ö¸¹Àº ¾÷¹« °úÁ¦, °¡Á· Àǹ« µî Àü·Ê ¾ø´Â »îÀÇ º¯È¸¦ °¡Á®¿Ô½À´Ï´Ù. ÀÌ´Â ¼ö¹é¸¸ ¸íÀÇ ¼ö¸é ÆÐÅÏ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Å« ½ºÆ®·¹½º°¡ µÇ¾î ½ÃÀå ¼ºÀåÀ» °ÈÇß½À´Ï´Ù. ¶ÇÇÑ ¸¸¼º ÅëÁõ, ¾Ï, ´ç´¢º´, ½ÉÀ庴, õ½Ä, À§½Äµµ¿ª·ùÁúȯ(GERD), °ú¹Î¼º °©»ó¼±, ÆÄŲ½¼º´, ¾ËÃ÷ÇÏÀ̸Ӻ´°ú °°Àº Áúº´Àº ÀϹÝÀûÀ¸·Î ºÒ¸éÁõ°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. µû¶ó¼ ÀÌ·¯ÇÑ Áúº´À» ¾Î°í ÀÖ´Â »ç¶÷µéÀÇ Áõ°¡´Â ºÒ¸éÁõ Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î, »ý¸®ÁÖ±â ¹× Æó°æ±âÀÇ È£¸£¸ó º¯È´Â ºÒ¸éÁõ ¹ßº´ÀÇ À§ÇèÀ¸·Î À̾îÁú ¼ö ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼ö¸é ÆÐÅÏ, Ȱµ¿, °Ç°ÀÇ º¯È ¹× 󹿾àÀÇ »ç¿ë Áõ°¡·Î ÀÎÇØ ³ëÀÎÀÇ ºÒ¸éÁõ °¡´É¼ºÀÌ ³ô¾ÆÁü¿¡ µû¶ó Àü ¼¼°è ³ëÀÎ Àα¸ÀÇ Áõ°¡´Â ºÒ¸éÁõ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÀÚ±ØÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºÒ¸éÁõ ¿¹¹æ, Áø´Ü, Ä¡·á ¹× °ü¸®¸¦ À§ÇÑ »õ·Î¿î Ä¡·á, ÁßÀç ¹× °Ë»ç ½ÃÇè¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡°¡ ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
º» º¸°í¼¿¡¼ ´Ù·ç´Â ÁÖ¿ä Áú¹®
- ºÒ¸éÁõ ½ÃÀåÀÇ ½ÃÀå ±Ô¸ð´Â?
- ºÒ¸éÁõ ½ÃÀåÀÇ ÇâÈÄ Àü¸ÁÀº?
- ºÒ¸éÁõ ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?
- ºÒ¸éÁõ ½ÃÀå Á¡À¯À²ÀÌ °¡Àå ³ôÀº Áö¿ªÀº ¾îµðÀΰ¡?
- ¼¼°è ºÒ¸éÁõ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº?
¸ñÂ÷
Á¦1Àå ¼¹®
Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý
- Á¶»ç ¸ñÀû
- ÀÌÇØ°ü°èÀÚ
- µ¥ÀÌÅÍ ¼Ò½º
- ½ÃÀå ÃßÁ¤
- Á¶»ç ¹æ¹ý
Á¦3Àå ÁÖ¿ä ¿ä¾à
Á¦4Àå ¼Ò°³
Á¦5Àå ¼¼°èÀÇ ºÒ¸éÁõ ½ÃÀå
- ½ÃÀå °³¿ä
- ½ÃÀå ½ÇÀû
- COVID-19ÀÇ ¿µÇâ
- ½ÃÀå ¿¹Ãø
Á¦6Àå ½ÃÀå ³»¿ª : Ä¡·á À¯Çüº°
- ºñ¾à¹°¿ä¹ý
- ÁÖ¿ä ºÎ¹®
- ÃÖ¸é¿ä¹ý
- ÀÎÁöÇൿġ·á
- ÀÇ·á±â±â
- ±âŸ
- ¾à¹°¿ä¹ý
- ÁÖ¿ä ºÎ¹®
- ó¹æ ¼ö¸é º¸Á¶Á¦
- OTC ¼ö¸é º¸Á¶Á¦
Á¦7Àå ½ÃÀå ³»¿ª : ¾à¹° Á¾·ùº°
- Ç׿ì¿ïÁ¦
- ¸á¶óÅä´Ñ ±æÇ×Á¦
- º¥Á¶µð¾ÆÁ¦ÇÉ
- ºñº¥Á¶µð¾ÆÁ¦ÇÉ°è ¾àÁ¦
- ¿À·º½Å ±æÇ×Á¦
- ±âŸ
Á¦8Àå ½ÃÀå ³»¿ª : À¯Åë ä³Îº°
- º´¿ø ¾à±¹
- ¼Ò¸Å ¾à±¹
- µå·°½ºÅä¾î
- ¿Â¶óÀÎ ¾à±¹
Á¦9Àå ½ÃÀå ³»¿ª : Áö¿ªº°
- ºÏ¹Ì
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- ÀϺ»
- Àεµ
- Çѱ¹
- È£ÁÖ
- Àεµ³×½Ã¾Æ
- ±âŸ
- À¯·´
- µ¶ÀÏ
- ÇÁ¶û½º
- ¿µ±¹
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ·¯½Ã¾Æ
- ±âŸ
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦10Àå SWOT ºÐ¼®
Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®
Á¦12Àå Porter's Five Forces ºÐ¼®
- °³¿ä
- ±¸¸ÅÀÚÀÇ ±³¼··Â
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- °æÀï Á¤µµ
- ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
Á¦13Àå °¡°Ý ºÐ¼®
Á¦14Àå °æÀï ±¸µµ
- ½ÃÀå ±¸Á¶
- ÁÖ¿ä ±â¾÷
- ÁÖ¿ä ±â¾÷ °³¿ä
- Astellas Pharma Inc.
- Aurobindo Pharma Limited
- Biocodex
- Eisai Co. Ltd.
- Mallinckrodt Pharmaceuticals
- Merck & Co. Inc.
- Neurim Pharmaceuticals Inc.
- Pfizer Inc.
- Sanofi S.A.
- Sumitomo Dainippon Pharma Co. Ltd.(Sumitomo Chemical Co. Ltd.)
- Takeda Pharmaceutical Company Limited
- Vanda Pharmaceuticals Inc.
ksm
¿µ¹® ¸ñÂ÷
The global insomnia market size was valued at USD 5.34 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 6.78 Billion by 2033, exhibiting a CAGR of 2.55% during 2025-2033. North America currently dominates the market, holding a significant market share of over 36.4% in 2024. Increasing prevalence due to modern lifestyles and stress, advancements in diagnostic technologies enhancing accuracy, robust research into novel therapies, rising healthcare expenditures, integration of digital health solutions, strategic industry collaborations, and growing consumer preference for non-pharmacological treatments are some of the factors bolstering the market growth. In addition to this, advanced healthcare, high sleep disorder prevalence, and adoption of innovative treatments are further increasing the insomnia market share.
Insomnia is a sleep disorder that can lower energy levels and affect the mood, health, work performance, and overall life quality of an individual. Its common causes include stress, long travels, hectic work schedules, poor sleep habits, binge eating, and excessive consumption of nicotine, caffeine, and alcohol. It can also be associated with mental health disorders, such as post-traumatic stress, and the use of drugs like antidepressants for asthma or blood pressure and over-the-counter (OTC) for pain relief, allergy, and cold. Its treatment options, such as cognitive-behavioral therapy (CBT), OTC sleep aids, and prescription medications like Eszopiclone and Ramelteon, are currently available worldwide.
Insomnia Market Trends:
The coronavirus disease (COVID-19) pandemic generated unprecedented changes in lives, including social isolation and innumerable work challenges and family obligations. This acts as a major stressful event that impacted the sleep patterns of millions and strengthened the market growth. Moreover, medical conditions, such as chronic pain, cancer, diabetes, heart disease, asthma, gastroesophageal reflux disease (GERD), overactive thyroid, Parkinson's disease, and Alzheimer's disease, are usually linked with insomnia. Hence, the increasing number of individuals suffering from these ailments is driving the demand for insomnia medications. Apart from this, hormonal shifts during the menstrual cycle and menopause can lead to the risk of developing insomnia, which is contributing to the market growth. In addition, as changes in sleep patterns, activity, and health and the rising use of prescription drugs can increase the chance of insomnia among older people, the growing geriatric population globally is catalyzing the demand for insomnia medical treatment. Furthermore, increasing investments in testing new treatments, interventions, and tests to prevent, detect, treat, and manage insomnia are anticipated to drive the market.
Key Market Segmentation:
Breakup by Therapy Type:
- Non-Pharmacological Therapy
- Hypnotherapy
- Cognitive Behavioral Therapy
- Medical Devices
- Others
- Pharmacological Therapy
- Prescription Sleep Aids
- Over-The-Counter Sleep Aids
Breakup by Drug Class:
- Antidepressants
- Melatonin Antagonist
- Benzodiazepines
- Nonbenzodiazepines
- Orexin Antagonist
- Others
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Astellas Pharma Inc., Aurobindo Pharma Limited, Biocodex, Eisai Co. Ltd., Mallinckrodt Pharmaceuticals, Merck & Co. Inc., Neurim Pharmaceuticals Inc., Pfizer Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co. Ltd. (Sumitomo Chemical Co. Ltd.), Takeda Pharmaceutical Company Limited and Vanda Pharmaceuticals Inc.
Key Questions Answered in This Report
- 1.How big is the insomnia market?
- 2.What is the future outlook of insomnia market?
- 3.What are the key factors driving the insomnia market?
- 4.Which region accounts for the largest insomnia market share?
- 5.Which are the leading companies in the global insomnia market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Insomnia Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Therapy Type
- 6.1 Non-Pharmacological Therapy
- 6.1.1 Market Trends
- 6.1.2 Key Segments
- 6.1.2.1 Hypnotherapy
- 6.1.2.2 Cognitive Behavioral Therapy
- 6.1.2.3 Medical Devices
- 6.1.2.4 Others
- 6.1.3 Market Forecast
- 6.2 Pharmacological Therapy
- 6.2.1 Market Trends
- 6.2.2 Key Segments
- 6.2.2.1 Prescription Sleep Aids
- 6.2.2.2 Over-The-Counter Sleep Aids
- 6.2.3 Market Forecast
7 Market Breakup by Drug Class
- 7.1 Antidepressants
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Melatonin Antagonist
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Benzodiazepines
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Nonbenzodiazepines
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Orexin Antagonist
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
8 Market Breakup by Distribution Channel
- 8.1 Hospital Pharmacies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Retail Pharmacies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Drug Stores
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Online Pharmacies
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Astellas Pharma Inc.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Aurobindo Pharma Limited
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.3 Biocodex
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.4 Eisai Co. Ltd.
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Mallinckrodt Pharmaceuticals
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.6 Merck & Co. Inc.
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 Neurim Pharmaceuticals Inc.
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.8 Pfizer Inc.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Sanofi S.A.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Sumitomo Dainippon Pharma Co. Ltd. (Sumitomo Chemical Co. Ltd.)
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.11 Takeda Pharmaceutical Company Limited
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.11.4 SWOT Analysis
- 14.3.12 Vanda Pharmaceuticals Inc.
- 14.3.12.1 Company Overview
- 14.3.12.2 Product Portfolio
- 14.3.12.3 Financials
°ü·ÃÀÚ·á